logo
Climate Crisis 'Evil Twin' Is Coming for Marine Life

Climate Crisis 'Evil Twin' Is Coming for Marine Life

Newsweek3 days ago

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Scientists have warned that the planet crossed the global boundary for ocean acidification around the year 2020, according to a new study.
Published in Global Change Biology, the study from Plymouth Marine Laboratory, NOAA and Oregon State University concludes that a key chemical threshold—set to prevent widespread harm to marine life—has already been exceeded.
The planetary boundary for ocean acidification is defined as a 20% decline from the pre-industrial aragonite saturation state, a measure of ocean water's ability to support calcifying organisms such as corals and shellfish.
March 3 2017, Great Barrier Reef, Cairns Australia. A diver swims over bleached staghorn coral, acropora, during the 2017 coral bleaching event on the Great Barrier Reef. Picture was taken on Pixie Reef.
March 3 2017, Great Barrier Reef, Cairns Australia. A diver swims over bleached staghorn coral, acropora, during the 2017 coral bleaching event on the Great Barrier Reef. Picture was taken on Pixie Reef.
Photo by Brett Monroe Garner / Getty Images
"The original boundary was characterized by two criteria: [First] that the polar regions do not reach undersaturation, and [second] that warm-water coral reefs do not fall below the marginal growth threshold," study author Helen Findlay told Newsweek in an email.
"We felt that neither of these things could be really assessed using a surface ocean global average figure without considering natural seasonal and regional variability, and so our study made the reassessment based also on regional changes."
Underestimating the Pace
Using updated models, the study found that the global average surface ocean had entered the boundary's uncertainty zone by 2020.
In deeper layers of the ocean, the findings are even more severe. At depths of 200 meters, 60% of the ocean had surpassed the acidification threshold.
Previous planetary boundary assessments, including those as recent as 2023, had judged ocean acidification to be nearing its critical limit but not yet beyond it.
The new analysis suggests that the original boundary may have underestimated the pace and reach of acidification.
It also reveals that the most affected regions include polar waters and the tropical zones that support the bulk of the world's coral reef systems.
'Now is the time'
"In our lifetimes (and by year 2100) we are committed to the ocean acidification that has already taken place," Findlay told Newsweek. "We cannot reverse that in the short term.
"Even if we were to stop emitting CO2 today, the ocean would remain at this level of ocean acidification for thousands of years."
However, Findlay noted that carbon dioxide removal and fewer emissions could speed the process up.
"Our models tell us that this is the decade for decisions," she told Newsweek. "For ocean acidification, the emissions pathways diverge around the year 2030, which means that now is the time to make the choice about how we minimize further damage."
How Ocean Acidification Happens
Ocean acidification occurs when carbon dioxide from the atmosphere dissolves into the ocean, changing the water's chemistry.
This process lowers the pH of seawater and reduces the amount of carbonate ions, which are essential building blocks for many marine creatures.
Animals like corals, oysters, clams and some types of plankton need carbonate to build their shells and skeletons. As acidification increases, it becomes harder for these organisms to grow and survive.
Findlay added that there has been misreporting that "all shellfish will die in the next 5-10 years".
"This is not the case," Findlay said. "Organisms are resilient when they are given the chance, but it is the rate of change that is important, and more likely that some local populations will survive and some may not."
Wide-Ranging Negative Effects
According to the researchers, habitat degradation has already become evident.
The study reports that suitable conditions for tropical coral reefs have shrunk by 43%, and for polar pteropods by up to 61%. Coastal regions vital for shellfish like oysters and mussels are also increasingly at risk.
Researchers propose redefining the ocean acidification boundary to a 10% decline from the pre-industrial saturation state to better protect marine biodiversity.
'Stick to the Paris Agreement targets'
When Newsweek asked about meaningful ways to combat acidification, Findlay explained, "Stop CO2 emissions! Stick to the Paris Agreement targets. Protect and restore ocean habitats and ecosystems. Minimize damage to the seafloor.
"Prevent the addition of nutrients and pollution in the coastal regions that can cause local acidification and therefore add to the overall global problem. Fund and support local communities to protect their local environment in a way that has sustainable benefits to them."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CEO Says New Tool Allows Couples To 'Genetically Optimize Their Children'
CEO Says New Tool Allows Couples To 'Genetically Optimize Their Children'

Newsweek

timean hour ago

  • Newsweek

CEO Says New Tool Allows Couples To 'Genetically Optimize Their Children'

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The CEO of a U.S.-based biotech company that developed software to enable parents to select embryos used for in vitro fertilization (IVF) based on genetic markers, told Newsweek that this "genetic optimization" would help people "live longer and thrive." Kian Sadeghi created his DNA testing and analysis company Nucleus to "give parents direct insights into whatever matters most to them when they choose their embryo." Nucleus offers the world's first genetic optimization software that allows parents to have preferences over their child's genetics during the IVF process, with the aim of reducing preventable genetic disease. "There's no moment when parents need to know how genetics will impact them and their loved ones more than when they're preparing to start a family," Sadeghi said. Genetic disease impacts millions of children in the U.S., with Down syndrome, Thalassemia, cystic fibrosis, Tay-Sachs disease and sickle cell disease among the most common. As well as screening for these sorts of conditions, Nucleus also analyses embryos for chronic conditions like Alzheimer's disease and heart disease. In total, it checks for almost 1,000 traits and conditions, from cystic fibrosis to heart disease, cancer risks, and mental health conditions like anxiety and ADHD. Kian Sadeghi, CEO of biotech company Nucleus, told Newsweek that "genetic optimization" would help people "live longer and thrive." Kian Sadeghi, CEO of biotech company Nucleus, told Newsweek that "genetic optimization" would help people "live longer and thrive." Newsweek/Getty Images/Canva Sadeghi said that many families "have experienced death at the hands of these common conditions and seek to prevent similar suffering." He told Newsweek that his own experience of the loss and grief brought on by genetic disease was actually what guided him to set up his company. When he was 7 years old, his 15 year-old cousin suddenly died in her sleep from what he said was a "preventable genetic disease." "My parents were heartbroken and terrified that my siblings and I would have the same fate," he said. Being so young at the time, Sadeghi said "it didn't make sense to me why someone would drop dead at 15, when other 15-year-olds are fine." He said that the loss of his cousin was the the first time he "intuitively grasped this idea of generational health." "Seeing this genetic lottery, when someone wins and someone doesn't, really stuck with me," he said. As he grew up, he developed a keen interest in genetics in school and by the time he got to college he was determined to create software that "could prevent what happened to my family from happening to anyone else in the world." After dropping out of the University of Pennsylvania, he then set up Nucleus in 2020, and believes that his software will spare families from the grief he himself felt when he lost a loved one to a preventable genetic disease. Kian Sadeghi, CEO of Nucleus, a company that has developed software to help parents screen their embryos for genetic conditions. Kian Sadeghi, CEO of Nucleus, a company that has developed software to help parents screen their embryos for genetic conditions. Uncredited/Nucleus Sadeghi added that his company is "democratizing access to genetic information," as at the moment, he said genetic testing results can be hard to decipher without a clear explanation from a doctor. "We're putting comprehensive, actionable data directly in parents' hands with tools that let them actually understand and compare their options," Sadeghi said. However, given that the software allows parents to genetically "optimize" their children, it raises various ethical questions, ones which members of the public have taken to social media to ask. Some social media users on X, formerly known as Twitter, voiced their concern that genetic screening could have unknown, secondary impacts, while others criticized Nucleus for oversimplifying the issue, saying "we can't predict longevity even for adults, so how can we possibly do this for embryos." Discussing ethical issues raised by the public, Sadeghi said, "until now, how this science would impact how we have children and how we would deploy it has been discussed only behind closed doors—not in public." He said now that Nucleus has announced the availability of the technology, the public has the opportunity to "listen to each other, hear each other out, and use this information to establish their views to ensure the insight Nucleus Embryo can provide is put to good use." Sadeghi added that the best way to have the public understand the technology was "to have them use it," and that it was important to make it accessible to as many people as possible. There have also been concerns raised about whether genetically optimizing IQ in embryos could increase risk of mental health conditions like schizophrenia. Sadeghi said that his company's report on schizophrenia risk for embryos noted that the condition is linked to both bipolar disorder, as well as intelligence, and that ADHD, OCD, Alzheimer's disease and autism were also linked to intelligence. He added that "we always educate parents on links between high disposition to neurological diseases and exceptional traits." "When you analyze genes for disease risk, you're also uncovering insights into traits, since both share a common genetic foundation," he said. The software, while being offered to parents to help them prevent their children from developing genetic disease, therefore does come with ethical considerations—considerations which will continue to be explored and discussed in public, now that the technology has brought the issue into the spotlight.

SpaceX Test Flight Suffers 'Major Anomoly'
SpaceX Test Flight Suffers 'Major Anomoly'

Newsweek

timean hour ago

  • Newsweek

SpaceX Test Flight Suffers 'Major Anomoly'

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. SpaceX has said its Starship rocket that exploded into a fireball shortly on Wednesday had suffered a "major anomaly" shortly before a schedule test flight. "All personnel are safe and accounted for," Elon Musk's space company said in a statement following the blast which occurred about 11pm at the Massey's Testing Center in Texas. "There are no hazards to residents in surrounding communities," it added. The statement posted on X, formerly Twitter, said: "On Wednesday, June 18 at approximately 11 p.m. CT, the Starship preparing for the tenth flight test experienced a major anomaly while on a test stand at Starbase. A safety clear area around the site was maintained throughout the operation and all personnel are safe and accounted for. On Wednesday, June 18 at approximately 11 p.m. CT, the Starship preparing for the tenth flight test experienced a major anomaly while on a test stand at Starbase. A safety clear area around the site was maintained throughout the operation and all personnel are safe and accounted… — SpaceX (@SpaceX) June 19, 2025 "Our Starbase team is actively working to safe the test site and the immediate surrounding area in conjunction with local officials. There are no hazards to residents in surrounding communities, and we ask that individuals do not attempt to approach the area while safing operations continue." This is a breaking news story. Updates to follow.

Scorpion Venom Could Help Treat Breast Cancer
Scorpion Venom Could Help Treat Breast Cancer

Newsweek

time13 hours ago

  • Newsweek

Scorpion Venom Could Help Treat Breast Cancer

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A venomous creature from the Amazon rainforest may hold the key to fighting one of the deadliest cancers affecting women today. According to the American Cancer Society, skin cancers aside, breast cancer is the most common cancer among women in the U.S.—accounting for about 30% of all new female cancer cases annually, with an estimated 42,170 women expected to die from it in 2025. Brazilian scientists have discovered that the venom of the Brotheas amazonicus scorpion contains a molecule that kills breast cancer cells in a way similar to chemotherapy, according to a groundbreaking study by researchers in Brazil. "Through bioprospecting, we were able to identify a molecule in the species of this Amazonian scorpion that is similar to that found in the venoms of other scorpions and that acts against breast cancer cells," said Eliane Candiani Arantes, a professor at the University of São Paulo and the project's coordinator. A stock image of a scorpion in the laboratory. A stock image of a scorpion in the laboratory. Sinhyu/iStock/Getty Images Plus The molecule in question, called BamazScplp1, is a type of peptide—a short chain of amino acids—that showed cancer-fighting properties when tested in the lab. It worka similarly to paclitaxel, a standard chemotherapy drug, by inducing necrosis, or uncontrolled cell death, in breast cancer cells. Unlike some other cell-killing processes that are regulated by the body, necrosis causes the cancer cells to burst and die—a tactic that has also been observed in other venom-based compounds. What Is Bioprospecting? Bioprospecting is the process of searching for useful compounds in nature, especially from plants, animals, and microorganisms. In this case, the team explored scorpion venom for potential bioactive molecules—substances that affect living tissues in a beneficial way, such as fighting infections or cancer. Turning Venom into Medicine—Without the Scorpions The researchers aren't milking scorpions for their venom at scale. Instead, they are using a process called heterologous expression, which means inserting the gene that produces a particular protein into another organism—often yeast or bacteria—so it can be produced in large quantities in the lab. "We also intend to obtain these molecules through heterologous expression," Arantes said, referring to BamazScplp1 and other promising compounds. One such host organism is Pichia pastoris, a species of yeast originally isolated in France in 1950. It's commonly used in biotechnology to manufacture proteins that would otherwise be difficult to source naturally. "Our idea now is to obtain this serine protease through heterologous expression [in a fragment or complete gene from a host organism that doesn't have it naturally] in Pichia pastoris," she added. The "Super Glue" Made from Snake Venom This isn't the first time researchers in Brazil have turned to venom for medical innovation. At the Center for the Study of Venoms and Venomous Animals (CEVAP), scientists developed a patented product called fibrin sealant—a kind of biological glue made by combining serinoproteinase (an enzyme found in snake venom) with cryoprecipitate, a component derived from the blood of buffalo, cattle, or sheep and is rich in fibrinogen, a protein essential for blood clotting. When mixed, the two form a fibrin network, mimicking the body's natural healing process. This sealant has been studied for uses like nerve repair, bone injury treatment and even helping restore movement after spinal cord injuries. It is currently in phase three clinical trials, the last stage before a drug can be considered for approval and widespread use. "This growth factor favors the formation of new vessels. If we combine it with colinein-1, we can create an improved fibrin sealant compared to the one being developed at CEVAP, with the possibility of expanding the industrial scale, since it can be obtained through heterologous expression," Arantes said. A Bigger Push Toward Biopharmaceutical Innovation All of this work is being carried out as part of the Center for Translational Science and Development of Biopharmaceuticals (CTS), a program aimed at turning biological discoveries into practical medical treatments. The CTS is part of a broader push by FAPESP, a public foundation in Brazil that funds scientific research. Their strategy isn't limited to scorpion venom. The team has also worked with rattlesnake proteins, including a compound called cholinein-1, and is developing another bioactive substance known as CdtVEGF, which promotes the growth of blood vessels—a potentially valuable tool in tissue regeneration. What Comes Next? The discovery of BamazScplp1 is still in the early stages. The results were shared at FAPESP Week France, a scientific conference held from June 10 to 12 in Toulouse, southern France. But the findings highlight the growing interest in nature-based compounds and how they might work alongside or even replace traditional treatments like chemotherapy. If further tests confirm its effectiveness and safety, the molecule from the scorpion could someday be developed into a new kind of anti-cancer drug, offering patients more options and possibly fewer side effects. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about breast cancer? Let us know via health@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store